

Date: 29 April 2025

Ref. No.: TCPCL/SEC/2025-26/00008

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

The Manager,
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex, Bandra(E),
Mumbai-400 051

Scrip Code: 543321

Scrip Symbol: TATVA

Subject: Fund raising by issuance of debt securities by Large Corporates

Ref.: Chapter XII of SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as updated on April 13, 2022 and SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023.

Dear Sir/Madam,

Pursuant to SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as updated on April 13, 2022 and SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, we hereby confirm that Tatva Chintan Pharma Chem Limited is not a Large Corporate as per the applicability criteria given under the above mentioned SEBI circulars.

The details as required in respect of Annual Disclosure are enclosed as Annexure - XII – B2.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Tatva Chintan Pharma Chem Limited

Ishwar Nayi
Company Secretary and Compliance Officer
M. No.: A37444

Encl.: As above

Annexure - XII – B2

Format of the annual disclosure to be made by an entity identified as a LC*
(to be submitted to the stock exchange(s) within 45 days of the end of the FY)

1. Name of the Company: **TATVA CHINTAN PHARMA CHEM LIMITED**
2. CIN: **L24232GJ1996PLC029894**
3. Report filed for FY: 2024-25 (T)
4. Details of the current block (all figures in Rs. crore):

Sr. No.	Particulars	Details
1.	2-year block period (specify financial years)	FY 2024-25 and FY 2025-26
2.	Incremental borrowing done in FY (T) (a)	N.A.
3.	Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)	N.A.
4.	Actual borrowing done through debt securities in FY (T) (c)	N.A.
5.	Shortfall in the borrowing through debt securities, if any, for FY (T-1) carried forward to FY (T). (d)	N.A.
6.	Quantum of (d), which has been met from (c) (e)	N.A.
7.	Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) {after adjusting for any shortfall in borrowing for FY (T-1) which was carried forward to FY (T)} (f) = (b)-[(c)-(e)] {If the calculated value is zero or negative, write "nil"}	N.A.

5. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs. crore):

Sr. No.	Particulars	Details
1.	2-year block period (specify financial years)	FY 2023-24 and FY 2024-25
2.	Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d)-(e)}#	N.A.

We confirm that **we are not a Large Corporate** as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021, as updated on April 13, 2022 and SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023.

For Tatva Chintan Pharma Chem Limited

Ishwar Nayi
Company Secretary
M. No.: A37444
Tel: +91 75748 48533
E-mail: cs@tatvachintan.com

Ashok Bothra
Chief Financial Officer
Tel: +91 75748 48533
E-mail: finance@tatvachintan.com

Date – 29/04/2025